se of an â??Oral Tabletâ?? to improve chances of Vaginal Delivery by softening the opening of the Womb(Cervix)
Not Applicable
- Registration Number
- CTRI/2021/04/033044
- Lead Sponsor
- Dr Yogindrakumar M Kabadi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
INCLUSION CRITERIA:
1.Singleton Pregnancy
2.Term gestation (37-42weeks)
3.Cephalic presentation
4.Intact membranes
5.Reactive fetal heart rate pattern in CTG
6.Consenting to participate in the study
7.Adequate pelvis
8.Unfavourable cervix with Modified Bishop
score <6
Exclusion Criteria
EXCLUSION CRITERIA:
1.Hypersensitivity to Mifepristone.
2.Cardiovascular, Renal, Hepatic disease, Asthma.
3.Cases of severe Pregnancy Induced Hypertension.
4.Any contraindication for vaginal delivery or
Mifepristone.
5. Abruption
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method changes in modified bishops scoreTimepoint: at 24 and 48 hours or whenever she comes with labor pain
- Secondary Outcome Measures
Name Time Method APGAR score and need for NICU admissionTimepoint: at birth of the newborn;maternal third stage complicationsTimepoint: at delivery and upto two hours after delivery;need for inductionTimepoint: at 48 hrs;ripening to delivery intervalTimepoint: at delivery